There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

2005;62(23):2410-2412. To increase the flexibility in preparation time and storage and decrease waste after reconstituting pantoprazole sodium for injection, it would be desirable to have a longer ...

Sanofi is reorganising its business units from seven to five in a bid to streamline its operations and ensure the success of its ambitious product launch plans. The revamp is the first major ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...

Rifamycin sodium CR is under clinical development by Cosmo Pharmaceuticals and currently in Phase II for Hepatic Encephalopathy. According to... Likelihood of Approval and Phase Transition Success ...

Sanofi India Limited (Previously known as Aventis Pharma Limited) was incorporated in May 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 2012. The ...

New Delhi: Responding to the proposal presented by Sanofi Healthcare for updating the prescribing information of Olipudasealfa Powder for concentrate for solution for infusion 20 mg vial, the Subject ...